Quantitative Study on HRCT Phenotype of COPD

Quantitative Study on HRCT Phenotype of the GOLD COPD Assessment Staging

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04953611

Enrollment

150

Registered

2021-07-08

Start date

2013-07-01

Completion date

2014-11-30

Last updated

2021-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

Pulmonary disease; chronic obstructive; Phenotype

Brief summary

To explore the HRCT phenotype of the combined COPD assessment staging system

Detailed description

HRCT can be rapidly and safely deployed has enabled COPD research to move beyond FEV1 by facilitating and amplifying clinical phenotyping measurements, providing quantitative information, and detecting significant responses to therapy even in the absence of significant FEV1 improvements. We explore the HRCT phenotype of the combined COPD assessment staging system,and found that: 1. Airway remodeling occurs in COPD patients. CT shows varying degrees of bronchial wall thickness, area increasing and emphysema as the new GOLD classification Group A-D arising. 2. The GOLD Combined assessment staging system helps doctors choose an individualized treatment for the COPD patients

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

1. Age between 40 and 80 (including 40 and 80) 2. It meets the diagnostic criteria for COPD 3. No language communication barriers, or the family members who know the condition can complete the questionnaire on behalf of the patient, and the data are reliable; 4. Voluntarily agree to participate in this study

Exclusion criteria

1. Older than 80 or younger than 40 2. Pregnant women 3. Complicating with other lung diseases, such as asthma, pneumonia, bronchiectasis, lung abscess, interstitial lung disease, confirmed and suspected lung cancer of lung shadow, active pulmonary tuberculosis, etc 4. Previous lung surgery 5. Cognitive dysfunction 6. Unable to cooperate with lung function test.

Design outcomes

Primary

Measure	Time frame	Description
The severity of emphysema	Within an average of 3 days after diagnosis of COPD	% low attenuation area \<950 HU (LAA %)
Indicator A of the severity of airway stenosis	Within an average of 3 days after diagnosis of COPD	The inner diameter of bronchial (LD) in centimeter
Indicator B of the severity of airway stenosis	Within an average of 3 days after diagnosis of COPD	The bronchial wall thickness in centimeter
Indicator C of the severity of airway stenosis	Within an average of 3 days after diagnosis of COPD	Ratio of thickness and outer diameter (TDR)
Indicator D of the severity of airway stenosis	Within an average of 3 days after diagnosis of COPD	% wall area for bronchial external diameter (WA%)

Countries

China

Outcome results